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In the United States, the number of patients
with end-stage renal disease (ESRD) has increased
each year, to a total of 300,000 in 1998.1 With the
growth of the hemodialysis program in the United
States, we find a decrease in the use of native arterio-
venous fistulas (NAVFs) and increased use of syn-
thetic arteriovenous grafts (AVGs) and silastic cuffed
catheters for permanent access.2,3 Some of the impe-
tus for this can be attributed to: (1) the lack of ade-
quate or easily identifiable superficial veins in
patients starting on hemodialysis who have a history
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Purpose: Recommendations recently published by the National Kidney Foundation—
Dialysis Outcome and Quality Initiative (DOQI) included an appeal for increased use of
native arteriovenous fistulas (NAVFs) to improve overall patency and contain angioac-
cess costs. We evaluated the impact of the DOQI recommendations on angioaccess
surgery and its outcome at our institution. 
Methods: From June 1996 to April 1999, 483 angioaccess procedures were performed on
247 patients. There were 133 men and 114 women, with an average age ranging from
28 to 95 years (mean age, 69 ± 0.59 years). Risk factors included smoking in 143
patients (58%), diabetes mellitus in 135 patients (55%), hypertension in 150 patients
(61%), and coronary artery disease in 98 patients (40%). The patients were divided in
two groups. Group I (pre-DOQI) included patients who had angioaccess procedures
between June 1996 and November 1997, and group II (post-DOQI) included patients
who had angioaccess procedures between December 1997 and April 1999. The types of
procedures performed included placement of arteriovenous grafts (AVGs) in 122
patients (25%), creation of NAVFs in 99 patients (20%), revision of AVGs in 123
patients (25%), and temporary access procedures in 135 patients (28%). Forty-seven of
the NAVF procedures were radial-cephalic fistulas (47%), 22 were brachial-cephalic fis-
tulas (23%), and 30 were brachial-basilic fistulas (30%). Patients underwent serial ultra-
sonography scanning and physical examinations; the mean follow-up period was 9
months. Choice of angioaccess procedures and patency rates before and after implemen-
tation of the DOQI recommendations were compared.
Results: There was a significant increase in the use of NAVFs after implementing DOQI
recommendations (5% vs 68%, P < .001). The 1-year primary patency rate of AVGs was
less than that of arteriovenous fistulas (54% vs 85%, P <.001). During the study period,
the percentage of AVGs placed at our institution that required revision (59%; 72 of 123)
was higher than that of NAVFs that required revision (4%; 4 of 99; P < .001). There was
no significant difference in the maturation rates of radial-cephalic fistulas (75%),
brachial-cephalic fistulas (91%), and brachial-basilic fistulas (87%).
Conclusion: By adopting the DOQI recommendations, we used NAVFs more often. This
resulted in superior patency rates, compared with synthetic grafts. The liberal use of pre-
operative duplex venous mapping further increased NAVF use, surpassing the DOQI
expectations for primary arteriovenous fistulas. Additionally, fewer revisions were
required. (J Vasc Surg 2000;31:84-92.)
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of multiple venipuncture or obesity; (2) earlier
access rates of AVGs compared with those of arte-
riovenous fistulas (AVFs); and (3) the relative ease of
placement of AVGs. However, because more proce-
dures are required to maintain AVG patency, com-
pared with that of AVF patency, hemodialysis access
failure has become the most frequent cause of hos-
pitalization among ESRD patients.4
To further investigate this issue, the National
Kidney Foundation—Dialysis Outcome and Quality
Initiative (DOQI) organized multidisciplinary work
groups that reviewed 3325 articles on the various
issues of ESRD in a 2-year period.5 They suggested
that native accesses have the best 4- to 5-year paten-
cy rates and require the fewest interventions, as
compared with other access types. To improve over-
all patency rates and help contain angioaccess costs,
the DOQI recommendations included, among
other things: (1) A minimum of 50% of new dialysis
patients electing to receive dialysis should have pri-
mary AVFs constructed; (2) Patients should be
reevaluated for possible construction of primary
AVF after failure of every dialysis arteriovenous
access; and (3) Cuffed catheters may be used for
patients who require immediate hemodialysis. Our
study was designed to evaluate the impact of the
DOQI recommendations on angioaccess surgery
and its outcome at our institution. 
PATIENTS AND METHODS
A retrospective review of the medical records of
the patients who underwent angioaccess procedures
from June 1996 to April 1999 found 483 angioac-
cess procedures were performed on 247 patients at
our institution. A total of 99 NAVFs, 122 AVGs,
123 graft revisions, four NAVF angioplasties, and
135 temporary access procedures were performed
during the period studied. The types of NAVFs con-
structed consisted of 47 radial-cephalic fistulas
(RCFs; 47%), 22 brachial-cephalic fistulas (BCFs;
22%), and 30 brachial-basilic fistulas (BBFs; 30%).
The patients included 133 men (56%) and 114
women (44%), with an average age ranging from 28
to 95 years (mean age, 69 ± 0.59 years). Risk factors
included diabetes mellitus in 135 patients (55%),
hypertension in 150 patients (61%), a history of
smoking in 143 patients (58%), and coronary artery
disease in 98 patients (40%). 
The DOQI recommendations were implement-
ed in December 1997. The patients were divided
into two groups. Group I (pre-DOQI) included
patients who underwent permanent angioaccess
procedures between June 1996 and November
1997, and group II (post-DOQI) included patients
who underwent permanent angioaccess procedures
between December 1997 and April 1999. Group I
included 110 patients and 216 procedures, whereas
group II had 137 patients and 267 procedures.
When a patient from group I required a new access
after the implementation of DOQI, the patient was
considered to be a new group II patient. There were
no significant differences between the groups in age,
sex distribution, and the incidence of the co-morbid
conditions.
In group II patients, clinical strategies, both pre-
operative and intraoperative, were used to maximize
the use of native AVFs . All patients underwent phys-
ical examination with outflow occlusion. Duplex
ultrasonography was used as a means of evaluating
venous anatomy in selected cases. The non-dominant
upper extremity was preferred to create angioaccess.
However, the final location of the NAVF was ulti-
mately determined by the size and quality of the
veins. Those patients who required immediate dialy-
sis received indwelling cuffed venous catheters (Tesio
catheter, Medcomp, Pa) for temporary venous access
while awaiting maturation of the fistula. A fistula was
considered immature when it could not be cannulat-
ed or was unable to support a blood flow rate higher
than 300 mL/s. Failure of maturation included cases
of steal that prevented the access from being used for
dialysis.
Upper-extremity venous mapping with
duplex ultrasonography. The deep venous system
was imaged with a 7-5 MHZ linear transducer while
the patient was in the supine position. Brachial veins
of the arm and the subclavian vein were studied to
rule out thrombosis and stenosis. This was particu-
larly relevant in patients who had previous access
procedures or central lines.6 For obese patients, a
lower frequency scanner (3-2 MHZ phased array or
5-2 MHZ curvilinear) was used to visualize the sub-
clavian vein.
Imaging of the superficial venous system was pri-
marily performed with a high-frequency scanner
(12-10 or 10-5 MHZ), which affords better B-
mode resolution and greater accuracy in the detec-
tion of intraluminal webs and synechiae.
The superficial system was assessed for compress-
ibility and diameter measurement of the vein in
cross-section at several levels. The cephalic vein was
evaluated from the wrist to the cephalic-subclavian
junction. When the cephalic vein at the wrist was less
than 2 mm in diameter with outflow occlusion, it
was not considered large enough to be used. The
basilic vein was studied at the upper forearm, elbow,
and arm. Upper arm veins larger than 3 mm were
considered to be adequate for placement of AVFs.
Additionally, the length of the basilic vein from ante-
cubital fossa to the junction with the deep venous
system was measured to evaluate whether the basilic
vein was long enough for formation of a fistula.
Visualization of the superficial venous system was
facilitated by means of the application of a tourniquet
at the upper arm. Segments of poorly compressible
segments of vein or veins with intraluminal webs in
the antecubital fossa were not considered for creation
of AVFs. Preoperative skin marking was performed in
obese patients, particularly for brachial-basilic or
brachial-cephalic fistulas and for those patients with
previous AVGs. 
Technique of radial-cephalic arteriovenous
fistula (RCF). Patients with a cephalic vein larger
than 3 mm in diameter were selected. With the
patient under local anesthesia with intravenous seda-
tion, a longitudinal incision between the radial
artery and the vein was made. After mobilizing the
cephalic vein, the vein was dilated with heparinized
saline solution, and an end-to-side anastamosis was
performed between the radial artery and the cephal-
ic vein. The sensory branch of the radial nerve was
carefully preserved. The fistula was allowed to
mature for 4 to 6 weeks before cannulation.
Technique of brachial-cephalic arteriovenous
fistula (BCF). With the patient under local anes-
thesia with intravenous sedation, the cephalic vein
was mobilized. The brachial artery was exposed by
using a separate incision or through the same inci-
sion. The cephalic vein was passed through a subcu-
taneous tunnel after venodilation, and an end-to-
side anastomosis was created by using a 6-mm arte-
riotomy. The fistula was allowed to mature for 4 to
6 weeks before cannulation.
Technique of brachial-basilic AVF (BBF). In
patients with poor cephalic veins, the basilic vein was
evaluated by means of preoperative duplex ultra-
sonography. The size of the vein and the location of
the basilic-brachial vein junction were evaluated.
Patients with a vein diameter of more than 3 mm
and a basilic-brachial vein junction in the upper one
third of the arm were selected for BBF. Those
patients with unsuitable anatomy for NAVF received
synthetic bridging grafts. 
The procedures were performed under general
anesthesia, axillary block, or local anesthesia. The
basilic vein was exposed through a medial longitudi-
nal incision. Care was taken not to injure the medi-
al cutaneous nerve of the arm during vein dissection.
All branches of the vein were isolated, ligated, and
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divided. The basilic vein was mobilized to its junction
with the brachial vein. The brachial artery at the level
of the distal arm was exposed by using the same inci-
sion.7 The basilic vein was transected close to the
elbow and distended with heparinized saline solution.
A subcutaneous tunnel was created by using an aortic
cross-clamp on the anterior aspect of the arm; the vein
was passed through this tunnel. A 6-mm arteriotomy
was made, and an end-to-side anastomosis was creat-
ed by using 6-0 polypropylene suture with the four-
quadrant technique. Additional care was taken to
secure hemostasis at the end of the procedure. 
Technique of arteriovenous graft placement.
The distal brachial artery and vein were dissected
through a transverse incision in the arm. A regular
wall 6-mm expanded polytetrafluoroethylene graft
was tunneled into the subcutaneous tissues of the
forearm as a loop with an aortic cross-clamp and a
counter incision on the distal forearm. A 6-mm arte-
riotomy was made, and an end-to-side anastomosis
was created by using 6-0 polypropylene suture with
the four-quadrant technique. When this was not
adequate, the loop graft was performed in the mid-
brachial artery and vein in the upper arm through a
longitudinal incision.
Follow-up. Patients underwent duplex ultra-
sonography scanning and physical examinations.
Hospital, office, and dialysis center charts were
reviewed and recent follow-up was obtained by
means of telephone interviews.
Statistical analysis. The choice of angioaccess
procedures and patency rates before and after
implementation of DOQI recommendations were
compared by means of the chi-square test (Winks
4.21, Texasoft, Texas). Graft and fistula patency
rates were determined by means of the life-table
method of analysis by using the statistical formulas
recommended by the Ad Hoc Committee on
Reporting Standards, Society for Vascular Sur-
gery/North American Chapter, International
Society for Cardiovascular Surgery.8 Life-table log-
rank comparison for statistically significant differ-
ences (P < .005) between life-table groups was per-
formed with SPSS software (version 9.0, SPSS
Science, Chicago, Ill). 
RESULTS
Procedures performed and patency rates. The
number of patients undergoing placement of NAVFs
significantly increased after the implementation of
the DOQI recommendations. A significant de-
crease in the number of angioaccess revisions (81
vs 45; P < .001) and a significant increase in the
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number of temporary venous access procedures
(103 vs 32; P < .001) performed during the post-
DOQI period was noted, compared with those per-
formed during the pre-DOQI period. The overall
patency rates of the angioaccess procedures
increased significantly in the post-DOQI period
(72% vs 45%; P < .001; Fig 1). 
The use of the native vein for the creation of an
AVF substantially increased after the implementation
of the DOQI recommendations (Fig 2). During the
last 6 months of the study, all new angioaccess pro-
cedures were NAVFs.
The primary patency rates of the NAVFs were
also significantly higher than that of the AVGs at the
end of 1 year (84% vs 54%; P < .001; Fig 3). The
patency rate of the angioaccess revisions (AVF and
AVG) was significantly lower than the primary
patency rate (57% vs 27%; P < .001; Fig 4). Because
none of the thrombosed NAVFs were revised, no
secondary patency rates for the NAVFs have been
reported. Of the four failing fistulas detected by
means of poor flow on dialysis, three were treated
with balloon angioplasty, and one was revised with
vein patch angioplasty. Because these failures
Fig 1. Overall patency rates before and after the implementation of the National Kidney
Foundation—Dialysis Outcome and Quality Initiative recommendations. There was a signifi-
cant improvement in the overall patency rate of the angioaccess procedures after the imple-
mentation of the National Kidney Foundation—Dialysis Outcome and Quality Initiative rec-
ommendations. DOQI, Dialysis Outcome and Quality Initiative.
Fig 2. Change in choice of angioaccess procedures with time. Note reversal of the number of
arteriovenous grafts placed, compared with the number of arteriovenous fistulas. AVG,
Arteriovenous graft; AVF, arteriovenous fistula.
JOURNAL OF VASCULAR SURGERY
88 Ascher et al January 2000
occurred at the end of the study period in a small
number of AVFs, the assisted patency rate of the
AVFs was not significantly different from the prima-
ry patency rate. All the NAVFs that underwent assist
procedures remained functional at the end of the
study. NAVFs required a significantly lower number
of revisions (4 of 99; 0.069 revisions per AVF per
year), compared with the number of revisions
required for AVGs (72 revisions for 122 AVGs newly
placed at our institution during the study period;
0.74 revisions per AVG per year; P < .001). The
overall follow-up period for groups I and II was 8.74
± 0.57 months. The mean follow-up period for the
patients with AVGs was 9.6 ± 0.87 months, and for
patients with AVFs, the mean follow-up period was
7.0 ± 0.58 months (P = .02).
Complications. Steal syndrome was identified in
four of the patients who had undergone placement
of NAVFs (4%). Ischemic ulcers at the finger tips
that required ligation of the NAVF developed in two
patients. The remaining two patients had symptoms
that improved with time. One of the AVG patients
(0.8%) had symptoms of steal syndrome and was
treated nonoperatively.
Certain complications were considerably higher
in the AVG group, including infections (11 [9%] in
the AVG group vs 1 [1%] in the NAVF group; P =
.001) and seromas (8 [6.5%] in the AVG group vs 0
in the NAVF group; P = .001). No significant dif-
ferences were observed in major and minor hema-
tomas between the groups.
Maturation. The maturation rates varied among
Fig 4. Primary patency rate (arteriovenous grafts plus arteriovenous fistulas) versus patency
rate of revisions (arteriovenous grafts plus arteriovenous fistulas). Revisions of the angioaccess
procedures were associated with a significantly lower patency rate when compared with the pri-
mary procedures.
Fig 3. Primary patency rate of arteriovenous fistulas versus arteriovenous grafts. Native arterio-
venous fistulas have significantly higher patency rates at the end of 1 year. The dotted line repre-
sents a greater than 10% standard error. AVG, Arteriovenous graft; AVF, arteriovenous fistula.
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the different types of NAVFs. RCFs had the lowest
6-week maturation rate, 75% (35 of 47 patients),
compared with 91% for BCFs (20 of 22 patients)
and 87% for BBFs (26 of 30 patients). These differ-
ences were not statistically significant (P = .3). 
Conversions from arteriovenous graft to
arteriovenous fistula. Of the 15 patients (12%)
who had thrombosed AVGs and underwent place-
ment of an AVF, five patients underwent RCF
placement, five patients underwent BCF place-
ment, and five patients underwent BBF placement.
Steal that necessitated closure of the AVF redevel-
oped in one patient who had a history of steal syn-
drome of the contralateral extremity. One patient
underwent a patch angioplasty of his AVF 5
months after placement. The remaining patients
have been using their AVFs without problems for a
mean of 7 months. 
Conversions from arteriovenous fistula to
arteriovenous grafts. Three of the patients with a
failed NAVF (3%) received an AVG. One patient had
undergone multiple failed AVF placements, and two
patients were found to have inadequate superficial
veins by means of duplex imaging and intraoperative
exploration.
DISCUSSION
The DOQI study recommends that primary
AVFs should be constructed in a minimum of 50% of
all new patients starting hemodialysis, because of the
poor long-term results of prosthetic angioaccess.7-12
This differs from the national data, which suggest
that only 30% of patients started on hemodialysis
have a primary AVF placed.9 In the present study,
80% of the patients in group II underwent primary
AVF. Further examination of the data reveals that
this figure may be an underestimation, because 95%
of the patients underwent primary AVF placement in
the last year of the review. The data presented in the
current review suggests that the DOQI guidelines
for the percentage of primary AVFs can easily be sur-
passed in this patient population by using a specific
protocol designed to maximize the use of autoge-
nous tissues for angioaccess.
The poor patency rates of AVG revisions in this
review concur with similar results obtained from
other centers, in which patency rates for revised
AVGs have ranged from 2.5% to 40% at 1 year.10-12
The AVF patency rates in this review are far superior
to the AVG patency rates, even when AVF revision
and failure of AVF maturation are included. These
rates reinforce the concept that AVG placement
should be a last-resort procedure. Additionally,
because AVF placement results in fewer long-term
complications, readmissions, and reoperations, sig-
nificant cost savings occur when the protocol is fol-
lowed. In 1998, $16 billion in private and public
funds was spent on ESRD. This figure has increased
an average of 10% per year for the last 5 years, mak-
ing the issue of angioaccess revision a major concern
when evaluating the escalating costs involved in
treating patients with ESRD.1
The protocol suggested by the DOQI guidelines
also has the advantage of not limiting future options.
For example, if a forearm RCF does not mature, the
upper-arm veins are still available for the next proce-
dure. If a BCF thromboses, then the option of a
BBF is still available. If all upper-extremity AVF
options have been exhausted, then placement of a
prosthetic AVG is still feasible through previously
undissected fields. However, the DOQI guidelines
recommend that when a BCF thromboses, then
either a BBF or a prosthetic AVG should be consid-
ered. As cited in the DOQI guidelines, drawbacks of
a BBF include cannulation difficulty because of vein
depth and a higher incidence of steal syndrome.
However, our preference has been to place a BBF
before prosthetic AVG placement. Because the
entire basilic vein is transposed to a superficial loca-
tion, it remains as simple to cannulate as any other
AVF. It remains unclear whether the rate of steal
syndrome found with BBF is higher than that of
other upper-extremity AVFs (0% to 3%).12,13 In our
limited series, the patients who underwent BBF
placement, as compared with those who underwent
AVG placement, had better patency rates with fewer
complications. These results are consistent with the
findings of other groups, which indicate that pros-
thetic AVG placement should only be used after all
autogenous options are exhausted.13-16
Although the DOQI guidelines do advocate that
each patient be evaluated for placement of an AVF
after AVG thrombosis, placement of an AVF in the
ipsilateral extremity after AVG thrombosis does entail
certain nuances. Preoperative duplex imaging was
used to assess the axillosubclavian vein. Although
none of these studies revealed areas of stenosis or
thrombosis of the axillosubclavian vein that may have
contributed to AVG thrombosis, we believe it should
continue to be an integral part of the preoperative
examination of patients with thrombosed angioaccess
who are undergoing placement of a new angioaccess
in the same extremity. Occasionally, a portion of an
overlying earlier thrombosed AVG was resected to
obtain adequate length of the upper-arm cephalic
vein for angioaccess (N = 4). In these instances, the
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overall results of the patients did not vary significant-
ly from that of the overall group with NAVFs.
Although this information base is limited, it does
suggest that patients with previous AVG placement
can enter this protocol and have good results.
Placing a BCF in a patient with a large amount
of subcutaneous fat overlying the cephalic vein can
also result in poor outcome, if certain measures are
not followed. For example, when there is more than
1 cm of subcutaneous fat overlying the cephalic vein,
it may remain inaccessible to the dialysis team, even
after the fistula has matured. This occurred in two of
our patients, and the vein had to be transposed to a
more superficial location. Because of this experience,
three additional patients underwent transposition of
the cephalic vein to a more superficial location at the
initial placement of the BCF.
Although placement of a Tesio catheter allows
time for maturation of the fistula or revision of the
fistula when needed, the Tesio catheter placement
also adds a small but not insignificant risk to the pro-
cedure in both the short and long term. The DOQI
guidelines recommend that patients be referred for
angioaccess placement when their creatinine level is
higher than 4.0 mg/dL, their creatinine clearance is
less than 25 mL/min, or within 1 year of the antic-
ipated need for dialysis. Only 9% of the patients we
reviewed did not need to have a catheter placed for
dialysis before fistula maturation. This obviously
indicates that patients are not being referred early
enough in their disease process to avoid the use of a
dialysis catheter. Greater emphasis of these guide-
lines to primary care providers for earlier referrals
clearly needs to be undertaken to initiate the proto-
col before urgent dialysis is needed.
Because of the small number of AVF revisions,
the inferences that may be drawn from this subset
are modest. However, we believe that because the
primary assisted patency rate of these AVFs seem
comparable with the primary patency rate of AVFs
without intervention, it may be worthwhile to inter-
vene on a failing or non-maturing AVF. The role of
serial screening with duplex imaging has not been
addressed in the literature and may, in time, prove to
have a major impact on this issue.
Although the DOQI study exhibited various
strengths and weaknesses, the guidelines it set forth
appeared to improve the overall results in our ESRD
patients. The results obtained in this study encour-
age us to continue following the DOQI guidelines;
however, long-term data analysis is necessary to
monitor the success of the DOQI recommenda-
tions. Because more centers are exploring these
guidelines, this ever-increasing segment of the pop-
ulation, and the system as a whole, should be able to
reap the benefits. 
REFERENCES
1. United States Renal Data System. USRDS 1999 annual data
report. The National Institutes of Health, National Institute
of Diabetes and Digestive and Kidney Diseases. Am J Kidney
Dis 1999;34:59-19.
2. United States Renal Data System. USRDS 1995 annual data
report. The National Institutes of Health, National Institute
of Diabetes and Digestive and Kidney Diseases. Am J Kidney
Dis 1995;26:S140-56.
3. Kaufman JL. The decline of the autogenous hemodialysis
access site. Semin Dial 1995;8:59-61.
4. Mayers JD, Markell MS, Cohen LS, Hong J, Lundin P,
Friedman EA. Vascular access surgery for maintenance
hemodialysis. Variables in hospital stay. ASAIO J 1992;38:
113-5.
5. The Vascular Access Work Group. NfK-DOQI clinical prac-
tice guidelines for vascular access. Am J Kidney Dis 1997;30
(Suppl 3):S150-91.
6. Silva MB Jr, Hobson RW II, Pappas PJ, Jamil Z, Araki CT,
Goldberg MC, et al. A strategy for increasing use of autoge-
nous hemodialysis access procedures: Impact of preoperative
noninvasive evaluation. J Vasc Surg 1998;27:302-7.
7. Hakaim AG, Nalbandian M, Scott T. Superior maturation
and patency of primary brachiocephalic and transposed basil-
ic vein arteriovenous fistulae in patients with diabetes. J Vasc
Surg 1998;27:154-7.
8. Ad Hoc Committee on Reporting Standards, Society for
Vascular Surgery/North American Chapter, International
Society for Cardiovascular Surgery. Suggested standards for
reports dealing with lower extremity ischemia. J Vasc Surg
1986;4:80-94.
9. United States Renal Data System. USRDS 1995 annual data
report. The National Institutes of Health, National Institute
of Diabetes and Digestive and Kidney Diseases. Am J Kidney
Dis 1998;32(Suppl 1):S2-162.
10. Brotman DN, Fandos L, Faust GR, Doscher W, Cohen JR.
Hemodialysis graft salvage. J Am Coll Surg 1994;178:431-4.
11. Bitar G, Yang S, Badosa F. Balloon versus patch angioplasty
as an adjuvant treatment to surgical thrombectomy of
hemodialysis grafts. Am J Surg 1997;174:140-2.
12. Marston WA, Criado E, Jaques PF, Mauro MA, Burnham SJ,
Keagy BA. Prospective randomized comparison of surgical
versus endovascular management of thrombosed dialysis
access grafts. J Vasc Surg 1997;26:373-8.
13. Matsuura JH, Rosenthal D, Clark M, Shuler FW, Kirby L,
Shotwell M, Purvis J, Pallos LL. Transposed basilic vein ver-
sus polytetrafluoroethylene for brachial-axillary arteriovenous
fistulas. Am J Surg 1998;176:219-21.
14. Butterworth PC, Doughman TM, Wheatley TJ, Nicholson
ML. Arteriovenous fistual using transposed basilic vein. Br J
Surg 1998;85:653-4.
15. Coburn MC, Carney W. Comparison of basilic vein and poly-
tetrafluoroethylene for brachial arteriovenous fistula. J Vasc
Surg 1994;20:896-904.
16. Rivers SP, Scher LA, Sheehan E, Lynn R, Veith FJ. Basilic
vein transposition: An underused autologous alternative to
prosthetic dialysis angioaccess. J Vasc Surg 1993;18:391-6.
Submitted Jun 8, 1999; accepted Sep 14, 1999.
JOURNAL OF VASCULAR SURGERY
Volume 31, Number 1, Part 1 Ascher et al 91
DISCUSSION
Dr Samuel E. Wilson (Orange, Calif). When I read a
report of a surgical series that ends with clinical recom-
mendations, before I adopt the advice, I make a point of
determining whether the study fulfills two requirements:
(1) Are the results overall, and especially in the control
subjects, comparable with what I see in my own experi-
ence and with those generally reported in the literature?
and (2) Are the patients described in the trial similar to
those in my own practice? If the answer to either of these
questions is no, the study has limited applicability.
This paper by Dr Ascher and colleagues, I am happy to
say, passes both tests. Their dialysis patients appear, in all
respects, to have the appropriate risk factors and demo-
graphics, and further, the 1-year patency rate of 54% for
arteriovenous polytetrafluoroethylene bridge grafts is right
on the mark.
Now, it is said—and I’m sure Dr Porter will agree—
that a happy man does not make a trustworthy critic.
Therefore, I have found worrisome areas to question.
First, the thrust of the quality assurance guidelines is
to reduce access-related hospitalizations. But I calculate
the overall number of procedures performed to be the
same in both periods, just fewer than two procedures per
patient per year. Why is that?
Second, you’ve increased the number of new autoge-
nous access procedures admirably, but at the cost of a con-
comitant threefold increase in percutaneous catheter
placements. Are you creating more axillosubclavian vein
thrombosis for the future? I’d include internal jugular
thrombosis, because this does occur.
Next, in the search, as you work harder for more com-
plicated arteriovenous fistula constructions, are you likely
to increase the number of postoperative complications, for
example, symptomatic steal after direct brachiocephalic fis-
tula? Wound complications are more common with the
brachium long incision required for basilic vein transloca-
tion.
Finally, the pivotal issue is have you met the overall
requirements of the quality initiative of 40% of your total
end-stage renal disease patients in your dialysis unit being
dialyzed with arteriovenous fistulas?
Congratulations, Dr Ascher and colleagues, on being
the first to put these National Kidney Foundation require-
ments into practice and for reinforcing the leadership role
of our Society by presenting your data here. Thank you.
Dr Anil Hingorani. Thank you very much, Dr Wilson;
we appreciate the work that you’ve done recently with
arteriovenous grafts and that you published in the March
edition of the Annals of Vascular Surgery. Yes, we looked
at your results for arteriovenous grafts and compared them
with ours and the numbers for the primary patency rates
for arteriovenous grafts and secondary patency rates. I
should say most of the patients and their the primary
patency rates were very similar, although your secondary
patency rates were appreciably better. The risk factors
from most of the literature has been somewhat similar.
You’re right, the number of procedures that are being
performed are similar between the two periods. And the
periods were actually quite similar, before and after imple-
mentation of the recommendations. Part of that, howev-
er, was also because of the Tesio removals and Tesio inser-
tions. Unfortunately, some of the patients had a Tesio
catheter or percutaneous catheter placed at a different
time than the arteriovenous fistula. This was mandated by
the nephrologists, because they didn’t feel the patients
needed a fistula at that time. And a fair number of the
patients required an arteriovenous fistula or secondary
procedure afterward. On the other hand, the patients,
when they had a Tesio removal, were counted as having
another procedure. That also inflated the number of pro-
cedures performed in the second part.
If you look at the total number of arteriovenous access
procedures that were performed in the first period, there
are 244. If you look at the number of arteriovenous access
procedures that were performed in the second period, it’s
almost half of that number. That’s excluding the Tesio
catheters.
Your concerns about more Tesio catheters being
placed is quite valid. We have been very fortunate to not
run into a lot of problems yet with subclavian vein throm-
bosis or stenosis. We do prefer to place these Tesio
catheters on the contralateral side in the arteriovenous fis-
tula when possible or in the right internal jugular. In the-
ory, this may result in fewer problems with subclavian vein
stenosis or thrombosis; however, we have seen patients
who have sustained subclavian thrombosis with IJ
catheters, such as central lines, pulmonary artery catheters,
and Tesios, and we reported these results approximately 2
years ago. Fortunately, the number of patients was quite
small.
Dr Frank T. Padberg, Jr (East Orange, NJ). Anil, I
compliment you on this interesting report, which demon-
strates the response of your institution to the National
Kidney Foundation—Dialysis Outcome and Quality
Initiative guidelines for hemoaccess. Your analysis, how-
ever, was limited to patency. In the dialysis population,
function is a more meaningful end point. Usually func-
tion is defined as the ability to cannulate the access con-
duit and perform a complete dialysis. Unfortunately, the
functional capacity of the access site was not reported by
the data that you’ve presented today. Did you analyze
these data for additional factors beyond patency? Could
these fistulas all be used? How did the increasing use of
catheters prevent you from getting access to this data?
Thank you.
Dr Hingorani. I’m sorry, we actually explained this in
the manuscript, and not in the talk. Patency was defined as
cannulation and the ability to support 300 mL/min of
dialysis. So, if the graft was patent and being used at 6
weeks, it was defined as mature and being in use.
Dr Joseph J. Hurley (St Louis, Mo). I appreciate the
thrust of the paper, Dr Hingorani. I have two questions,
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one related to Dr Padberg’s question. You have had four
revisions in 99 patients, and yet you quoted a 16% matu-
ration failure; I’m a little bit confused about that.
Second, you obviously frequently used the noninvasive
laboratory in the duplex scanning of these veins. Do you
have any recommendations, based on your experience,
about the minimal size of vein for an all autogenous pro-
cedure, which obviously is superior?
Thank you.
Dr Hingorani. The four revisions were for fistulas that
were already working and became dysfunctional, obtain-
ing high pressures or low flows. The 16% failure of matu-
ration rate was for fistulas that were never used to start
with. They never matured in the 6-week period, so those
were a separate category.
Even when we exclude those patients, or look at the
patency rates with intent to treat, the statistical differences
do not change. Even when you add in that 16% rate of fail-
ure of maturation, the primary patency rates between the
arteriovenous grafts and the arteriovenous fistulas still dif-
fer at 1 year.
Based on the duplex data, we try to use veins larger
than 3 mm in diameter, but we also try to look at the area
of stenoses, areas of synechia, and outflow obstructions.
Dr Porter. Does that answer your question?
Dr Hurley. Basically. The only other question is did you
do any particular maneuvers when you tried to assess the
veins? We know that, looking at the veins in the lower
extremity, we get a better size when the patients stand
than when they’re supine. Did you put cuffs on, dangle
the arm, or anything like that?
Dr Hingorani. Yes, outflow obstruction was used rou-
tinely.
Dr Mauro Gargiulo (Rimini, Italy). I enjoyed your
paper very much. In Europe and in Italy, the first approach
is native arteriovenous fistulas, and the second approach
and choice is the graft. I have two questions.
First, how do you study the arm arteries before you
make the access?
Second, how do you follow the fistulas in the postop-
erative period?
Thank you.
Dr Hingorani. Pulmonary vascular resistance was used
routinely in the post-volume recordings, and PPGs were
used routinely for the patients preoperatively.
Also, the dialysis centers to which we send patients get
creatinine clearances, pressures, etc. And if the pressure
steadily increases, we become concerned about a stenosis
developing. Selected patients also underwent routine seri-
al duplex imaging of the fistula.
